Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone

Shereen Elazzazy,1 Saad S Eziada,2 Manal Zaidan11Pharmacy Department, 2Oncology Hematology Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarAbstract: Concomitant administration of atorvastatin, omeprazole, and dexamethasone has been shown to increase th...

Full description

Bibliographic Details
Main Authors: Elazzazy S, Eziada SS, Zaidan M
Format: Article
Language:English
Published: Dove Medical Press 2012-09-01
Series:International Medical Case Reports Journal
Online Access:http://www.dovepress.com/rhabdomyolysis-secondary-to-drug-interaction-between-atorvastatin-omep-a10902
id doaj-cef66dcce6f241e7b0ab4d2cd6099cf6
record_format Article
spelling doaj-cef66dcce6f241e7b0ab4d2cd6099cf62020-11-24T22:59:32ZengDove Medical PressInternational Medical Case Reports Journal1179-142X2012-09-012012default5961Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasoneElazzazy SEziada SSZaidan MShereen Elazzazy,1 Saad S Eziada,2 Manal Zaidan11Pharmacy Department, 2Oncology Hematology Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarAbstract: Concomitant administration of atorvastatin, omeprazole, and dexamethasone has been shown to increase the serum concentration of serum hydroxymethylglutaryl coenzyme A which can be associated with elevation of creatine kinase and an increased risk of severe myopathy and rhabdomyolysis. In this paper, we report a case of a 60-year-old female patient with stage IV colon cancer and compromised hepatic function receiving palliative care who developed rhabdomyolysis while taking atorvastatin, omeprazole, and dexamethasone. Atorvastatin was stopped, and the dexamethasone dose was decreased. Her case was complicated by urosepsis cultures revealing an extended spectrum β-lactamase-producing strain of Escherichia coli, and she died on the second day after admission. Physicians should evaluate the risk/benefit ratio of continuing statins in palliative care patients, and pay special attention to the monitoring of patients on statins and P-glycoprotein inhibitors regardless of hepatic function.Keywords: statins, rhabdomyolysis, drug–drug interaction, P-glycoprotein inhibitorshttp://www.dovepress.com/rhabdomyolysis-secondary-to-drug-interaction-between-atorvastatin-omep-a10902
collection DOAJ
language English
format Article
sources DOAJ
author Elazzazy S
Eziada SS
Zaidan M
spellingShingle Elazzazy S
Eziada SS
Zaidan M
Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone
International Medical Case Reports Journal
author_facet Elazzazy S
Eziada SS
Zaidan M
author_sort Elazzazy S
title Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone
title_short Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone
title_full Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone
title_fullStr Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone
title_full_unstemmed Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone
title_sort rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone
publisher Dove Medical Press
series International Medical Case Reports Journal
issn 1179-142X
publishDate 2012-09-01
description Shereen Elazzazy,1 Saad S Eziada,2 Manal Zaidan11Pharmacy Department, 2Oncology Hematology Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarAbstract: Concomitant administration of atorvastatin, omeprazole, and dexamethasone has been shown to increase the serum concentration of serum hydroxymethylglutaryl coenzyme A which can be associated with elevation of creatine kinase and an increased risk of severe myopathy and rhabdomyolysis. In this paper, we report a case of a 60-year-old female patient with stage IV colon cancer and compromised hepatic function receiving palliative care who developed rhabdomyolysis while taking atorvastatin, omeprazole, and dexamethasone. Atorvastatin was stopped, and the dexamethasone dose was decreased. Her case was complicated by urosepsis cultures revealing an extended spectrum β-lactamase-producing strain of Escherichia coli, and she died on the second day after admission. Physicians should evaluate the risk/benefit ratio of continuing statins in palliative care patients, and pay special attention to the monitoring of patients on statins and P-glycoprotein inhibitors regardless of hepatic function.Keywords: statins, rhabdomyolysis, drug–drug interaction, P-glycoprotein inhibitors
url http://www.dovepress.com/rhabdomyolysis-secondary-to-drug-interaction-between-atorvastatin-omep-a10902
work_keys_str_mv AT elazzazys rhabdomyolysissecondarytodruginteractionbetweenatorvastatinomeprazoleanddexamethasone
AT eziadass rhabdomyolysissecondarytodruginteractionbetweenatorvastatinomeprazoleanddexamethasone
AT zaidanm rhabdomyolysissecondarytodruginteractionbetweenatorvastatinomeprazoleanddexamethasone
_version_ 1725644897525956608